BioInvent International AB (CHIX:BINVS) Notes Receivable: kr0.0 Mil (As of Mar. 2026)


CHIX:BINVS BioInvent International AB CHIX:BINVS
39 GF Score
Price kr34.75
GF Value kr67.41
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Notes Receivable?

BioInvent International AB CHIX:BINVS 39 Notes Receivable is kr0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:BINVS with a GF Score™ of 39/100 and a GF Value™ of kr67.41. The stock has 4 warning signs investors should review.

BioInvent International AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.0 Mil.

BioInvent International AB Notes Receivable Related Terms

BioInvent International AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Notes Receivable Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:BINVS
39GF Score
BioInvent International AB CHIX:BINVS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.0 Mil mean?
BioInvent International AB (CHIX:BINVS) has a Notes Receivable of kr0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Notes Receivable too high?
BioInvent International AB's current Notes Receivable is kr0.0 Mil. Overall, BioInvent International AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Notes Receivable compare to VRTX and REGN?
BioInvent International AB's Notes Receivable of kr0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Notes Receivable is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (CHIX:BINVS) has a current Notes Receivable of kr0.0 Mil. The stock's GF Value™ is kr67.41, compared to a current price of kr34.75 — trading 48.4% below its estimated fair value. The current Notes Receivable is kr0.0 Mil. BioInvent International AB's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For BioInvent International AB (CHIX:BINVS), the current Notes Receivable is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (CHIX:BINVS) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr34.75 is trading 48.4% below its estimated GF Value™ of kr67.41.

Key valuation signals for CHIX:BINVS:

  • Notes Receivable: kr0.0 Mil
  • GF Value™: kr67.41 vs. price of kr34.75 (48.4% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BINVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score

Get the complete analysis for CHIX:BINVS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.75
Price
kr67.41
GF Value